Cost-effectiveness analysis of ribociclib versus palbociclib as a first line therapy in HR+/HER2- advanced breast cancer: evidence from the Chilean Public Health system

Ribociclib plus letrozole is cost-saving and cost-effective compared to palbociclib plus letrozole for the first-line treatment of postmenopausal women with HR+/HER2- advanced BC in Chile.